semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Oral Hygiene Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/dental examination A minimum of 20 permanent gradable teeth Moderate gingivitis present at the screening visit in the opinion of the investigator A total of 20 bleeding sites or greater at baseline visit Positive response to bleeding on brushing present at the screening visit  Pregnant or breast feeding women Tobacco chewers Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participant or undermines the data validity Recent history (within the last year) of alcohol or other substance abuse Participants requiring prophylactic antibiotic treatment prior to dental therapy Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients Have current active caries or any medical conditions which may directly influence gingival bleeding Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index Participation in another clinical study or receipt of an investigational drug or oral care product within 30 days of the screening visit
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Oral Hygiene Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/dental examination A minimum of 20 permanent gradable teeth Moderate gingivitis present at the screening visit in the opinion of the investigator A total of 20 bleeding sites or greater at baseline visit Positive response to bleeding on brushing present at the screening visit  Pregnant or breast feeding women Tobacco chewers Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participants or undermines the data validity Recent history (within the last year) of alcohol or other substance abuse Participants requiring prophylactic antibiotic treatment prior to dental therapy Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients Have current active caries or any medical conditions which may directly influence gingival bleeding Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index Participation in another clinical study or receipt of an investigational drug or oral care product within 30 days of the screening visit
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Hypophosphatasia Bone Disease Documented informed consent/assent prior to video collection and data abstraction Documented informed consent/assent in Study ALX-HPP-502 Patients with juvenile-onset HPP and was selected as a historical-control for Study ENB-006-09 Patients with at least 2 videos of basic mobility that were recorded at 2 different clinic visits when the patient was ≥5 to ≤15 ye  There are no for this study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypophosphatasia Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent Patients must have a pre-established clinical diagnosis of HPP, as indicated by one or more of the following Serum alkaline phosphatase (ALP) below the age-adjusted normal range Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination) Evidence of osteopenia or osteomalacia on skeletal radiographs Genetic analysis fof the ALPL gene  Any patient without confirmation of clinical diagnosis of HPP
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Esophageal and Gastric Varices Ulcer Cirrhosis Hypertension, Portal Patient with esophageal varices having upper GIT endoscopy  Patients having endoscopy with no EVs
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  GERD A medical diagnosis of GERD 2. Awakening with a taste of refluxed stomach acid in the mouth 3. Heartburn during sleep 4. Voice hoarseness upon awakening 5. Antacid use at night 6. Dry mouth at bedtime or during the night 7. Experience difficulty chewing, swallowing, and speaking because of dry mouth  Under 18 2. Prior history of any of these conditions: 1. coronary artery disease 2. gallbladder disease 3. gastric or esophageal cancer 4. peptic ulcer disease 5. esophagitis, whether eosinophilic, infectious, or pill based 6. esophageal motility disorders 3. A history of thoracic, esophageal, or gastric surgery 4. No medical examination in the prior year
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Otitis Media With Effusion Eustachian Tube Disorder Patients > 18 years old Referred to ENT clinic at Rikshospitalet for evaluation and treatment of OME, tympanic membrane peroration or tympanic membrane retraction Dysfunction of the ET is suspected by the ENT surgeon The patient is a candidate for balloon dilation of the ET  Previous serious allergic reaction to iodine based contrast medium Increased risk of bleeding Serious heart disease Diabetes I Previous ENT-surgery (t-tubes excluded) Middle ear disease, which requires other type of treatment Chronic rhino sinusitis or nasal polyposis Pregnancy
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-60.0,  Molar, Third Wisdom Teeth any patients requiring bilateral lower third molars extracted of similar technical difficulty under general anaesthesia  any intra-operative complications any post-operative complications, including infection if the extractions end up being too dissimilar surgically any contra-indication to the Hilotherm mask patients with any immune system-affecting diseases patients with allergies to pharmaceutical drugs (eg. analgesics or antibiotics)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Osteoporosis Men and women above the age of 60 years. 2. Underwent Dental Cone Beam Tomography for dental reasons, up to three months before screening. 3. Patients underwent bone density examination at Soroka Medical Center only, during the last year prior commencing the research will be eligible for participation without the need for an additional bone density scanning  Patients with current or past treatment of any osteoporotic medication: Alendronate (Alendronate teva, Fosamax, Maxibone , Fosalan, Fosavance), Residronate (Actonel. Ribone), Zoledronic acid (Aclasta, Zomera), Denosumab (Prolia), Teriperatide (Forteo),Raloxifen ( Evista), Stronsium Ranelate (Protelos). 2. Patients taking Corticosteroid Therapy. 3. Patients with history of Head and Neck Neoplasia or Head and Neck Irradiation or Bone Metastasis. 4. Patients with hard tissue pathology of the jaws. 5. Patients after laminectomy and or fixation of lumbar vertebrae or after bilateral hip replacement. 6. Diagnosis of primary hyperparathyroidism
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Pressure Ulcer Diabetes Mellitus Type 2 Charcot- Osteoarthropathy Group A Healthy volunteers > 40 years Group B patients with Diabetes Mellitus type 2 (DM) without neuropathy age > 40 years Valk score < 4 Group C Patients with DM type 2 with neuropathy age > 40 years Valk score > 4 Group D Patients with (pre)  Trauma fore arms Skin diseases (psoriasis, eczema) NSAID use in last seven days Bèta blocker use Corticosteroids Auto immune diseases Muscular dystrophy Malignancy Participant is unable to give informed consent
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 8.0-17.0,  Migraine Present to the emergency department with a migraine headache as defined by the modified Irma criteria. The modified Irma are as follows: Headache episodes of 1-168 hours (7 days) presenting with at least 3 of the following 6 moderate to severe episode of impaired daily activities; focal localization of headache; pulsatile description; nausea or vomiting or abdominal pain; photophobia or phonophobia or avoidance of light and noise; symptoms increasing with activity or resolving by rest Headache severity of moderate to severe pain (i.e. at least 4/10 on the Faces Pain Scale Revised) Requiring IV fluids and any IV medication (for example: ketorolac, metoclopramide, prochlorperazine, ondansetron) as part of their headache treatment, as per their treating attending physician  Contraindication to receiving ketorolac Receipt of an NSAID within six hours of study drug administration Presence of an intranasal obstruction that cannot be readily cleared Inability to speak English or Spanish Unable to complete self-report measures of pain or questionnaires Critical illness Frequent use of drugs for headache (i.e. regular intake of analgesics for acute headaches on more than 10 days per month)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-64.0,  Chronic Disease Obesity Hypertension Diabetes Self Care Medication Adherence AA (based on self-report) 2. self-reported male 3. aged at least 21 years 4. non-institutionalized (i.e., community-dwelling, not living in assisted living facilities, nursing homes, etc.) 5. at high risk for developing chronic disease (e.g., not meeting current guidelines for PA and/or F&V intake; current smoker; diagnosed with high cholesterol) or 6. currently diagnosed with diabetes, hypertension, or cardiovascular disease 7. residents of Forsyth County, NC (or surrounding areas and able to attend group sessions in Forsyth County)  have had a cardiovascular procedure (e.g., heart surgery), heart attack, heart failure, stroke in the last 6 months 2. have cognitive, visual, auditory, physical functional (e.g., unable to walk unassisted), or language impairment precluding participation in group discussion, learning activities, or data collection. 3. currently achieve >150 min/wk of moderate intensity PA or >75 min/wk of vigorous intensity PA AND currently consume > 9 servings of F&V daily. 4. are currently enrolled in a chronic disease management program. 5. are unwilling to accept randomization assignment or planning to move from local area in <2 years. 6. are currently receiving chemotherapy/radiation treatments. Participants will be required to obtain approval from a health care provider prior to participation in the study if they: 1. are unable to participate in moderate PA due to physical limitations as indicated by positive (risk) responses on the PA Readiness Questionnaire (PAR-Q) and/or physician disapproval on the PAR Medical Examination. 2. have BP>180/>110 and/or HbA1C>12 and/or triglycerides >500. 3. have health conditions that could preclude changes to diet (e.g., irritable bowel syndrome, celiac disease)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lymphedema years of age or older Patients undergoing a primary elective total knee arthroplasty The patient is able to understand the study and is willing to give written informed consent to the study  Allergy against one of the used materials Severe systemic diseases causing peripheral oedema Acute superficial or deep vein thrombosis Arterial occlusive disease (stadium II, III or IV) ABPI<0,8 Local infection in the therapy area auto-immunological disorders or vasculitis use of systemic corticosteroids Inability to don, doff, and adjust the device
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Mitral Valve or Aortic Valve Replacement The patients who implanted with Perimount Heart Valve (Type: 6900P and 2900) during 2001-2007 in Guangdong General Hospital in China The patients agree to join the study and sign the ICF  No specific